TY - T1的治疗水平的惯性与协议MS治疗的景观(p1.2 - 101)摩根富林明-神经学乔-神经学六世- 92 - 15补充SP - p1.2 Jiwon哦- 101 AU - AU -法比Bakdache盟费尔南多·卡塞雷斯AU -阿隆索蒙托首页亚盟Gustavo Saposnik Y1 - 2019/04/09 UR - //www.ez-admanager.com/content/92/15_supplement/p1.2 - 101. -文摘N2 -目的:评估个人的协议之间的关系图验证了专家,女士描述现有的疾病修饰治疗的相对安全性和有效性(儿童)复发女士(图:https://goo.gl/UrVRtd)和治疗惯性(TI)的患病率在神经学家从阿根廷。与专业知识背景:神经学家面临的挑战裁剪女士治疗决定基于最优平衡相关的安全性和有效性的不断变化的景观疗法。设计/方法:117神经专业女士回答问题的管理模拟临床情况下和一个图表示与儿童的安全性和有效性的概要文件。参与者认为他们同意图使用一个模拟视觉范围从清廉(还没有完整的协议)。TI是归类为分类(yes / no)和连续变量通过创建一个得分从0到8。钛被定义为缺乏治疗升级当有明确证据的临床和放射学活动(8例场景)。结果:90年神经(76.9%)完成了研究。TI出现在74.4%的参与者在至少一个的情况。平均TI评分(SD)为1.7 (1.4)。协议与景观图的平均水平是8.1(标准差1.9)。参与者协议率较低(≤6 10)有一个TI平均分数与同行相比要高(2.33 vs 1.60;p = 0.10)。After adjusting for age, being an MS specialist, years of practice, and volume of patients seen per week, the agreement with the MS treatment figure was associated with lower incident risk of TI (OR 0.88; 95%CI 0.79–0.97).Conclusions: A higher level of agreement with a figure depicting the safety and efficacy of existing MS DMTs was independently associated with a lower incident risk of TI. These results suggest that a single question may be useful to identify neurologists prone to exhibiting TI.Disclosure: Dr. Oh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, EMD Serono, Genzyme, Novartis, Roche. Dr. Oh has received research support from Biogen Idec, Genzyme, MS Society of Canada, Teva. Dr. Bakdache has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Hoffmann-La Roche Ltd. Dr. Caceres has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen. Dr. Montoya has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Hoffmann-La Roche Canada. Dr. Saposnik has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, EMD Serono, Sanofi Genzyme, Novartis Pharmaceuticals,and Roche. Dr. Saposnik has received research support from Roche Boheringher. ER -